Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

Why is the Colon Recurrence Score® test the test of choice?

The Oncotype DX Colon Recurrence Score® test has Level 1 evidence and is backed by robust data from 4 validation studies. These data confirm that the results predict risk of local recurrence.1-4

The Colon Recurrence Score test vs traditional assessment methods

Traditional clinical and pathologic factors provide some prognostic insight, but they can’t quantify individual risk of recurrence for patients with colon cancer. As a result, helping your patient make appropriate treatment decisions with clinical and pathologic factors alone can be difficult.

The Colon Recurrence Score test offers a precise and more accurate estimate of recurrence risk, helping you determine adjuvant treatment for your patient with anatomic stages II MMR-P or III A/B colon cancers.1-4

The information you need for personalized treatment decisions

The Colon Recurrence Score test goes beyond traditional measurements (nodal assessment, bowel perforation or obstruction, tumor grade, lymphatic or venous invasion, T-stage, and MMR status) to predict each patient’s individualized risk of recurrence. It does so by looking at the unique biology of the tumor sample removed during their surgery.

Unlike pathologic and clinical methods, Colon Recurrence Score results1-4:

  • Reflect the individual biology of each patient’s tumor, offering a more complete picture of your patient’s unique risk
  • Quantify risk of recurrence for anatomic stage II MMR-P patients and stage III A/B patients
  • Highlight the importance of biologic information (ie, MMR and Recurrence Score® result)

In addition, the Colon Recurrence Score report can help enhance the patient conversation when discussing risk and treatment options. Learn more about the Colon Recurrence Score results.

Practical, actionable insights for anatomic stage II MMR-P and stage III A/B patients

A high Recurrence Score® result

Can identify anatomic stage II MMR-P patients who have a higher risk of recurrence1-4

These patients can expect a greater absolute benefit from chemotherapy after their surgery

A low Recurrence Score result

Can identify anatomic stage III A/B patients who have lower-than-average risk of recurrence3,4

These patients can expect a lower absolute benefit from the addition of oxaliplatin to 5-FU/LV

The benefits of genomic testing

The Colon Recurrence Score test examines the activity of 12 genes in a patient’s tumor. The Colon Recurrence Score test looks at the activity of these genes to help you and your patient make decisions about treatment.

Order the Test Now